TMS is not experimental; it was cleared by the FDA in 2008 to help people fight depression and in 2022 for decreasing anxiety symptoms in adult patients suffering from major depressive disorder and as an adjunct therapy for adults with OCD. Today, NeuroStar is the top TMS choice of doctors, and over 5.6 million treatments have been delivered.